Targeted therapies for brain metastases from breast cancer

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Venur, Vyshak Alva ^a   Leone, José Pablo ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Brain metastases; Breast cancer; CDK 4 6; EGFR; HER2; MTOR; PI3K; VEGF

Indexed keywords

ABEMACICLIB; AFATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NERATINIB; PALBOCICLIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CEREBROSPINAL FLUID ANALYSIS; HUMAN; IMMUNE SYSTEM; PHOSPHORYLATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; STEREOTACTIC RADIOSURGERY; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84987704177     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091543     Document Type: Review

References (63)

1. Lin, N.U.; Amiri-Kordestani, L.; Palmieri, D.; Liewehr, D.J.; Steeg, P.S. CNS metastases in breast cancer: Old challenge, new frontiers. Clin. Cancer Res. 2013, 19, 6404-6418. [CrossRef] [PubMed]
2. Arslan, C.; Dizdar, O.; Altundag, K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin. Pharmacother. 2010, 11, 1089-1100. [CrossRef] [PubMed]
3. Smid, M.; Wang, Y.; Zhang, Y.; Sieuwerts, A.M.; Yu, J.; Klijn, J.G.M.; Foekens, J.A.; Martens, J.W.M. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68, 3108-3114. [CrossRef] [PubMed]
4. Leone, J.P.; Leone, B.A. Breast cancer brain metastases: The last frontier. Exp. Hematol. Oncol. 2015, 4, 33. [CrossRef] [PubMed]
5. Venur, V.A.; Ahluwalia, M.S. Prognostic scores for brain metastasis patients: Use in clinical practice and trial design. Chin. Clin. Oncol. 2015, 4, 18. [CrossRef] [PubMed]
6. Sperduto, P.W.; Berkey, B.; Gaspar, L.E.; Mehta, M.; Curran, W. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the rtog database. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 510-514. [CrossRef] [PubMed]
7. Sperduto, P.W.; Kased, N.; Roberge, D.; Xu, Z.; Shanley, R.; Luo, X.; Sneed, P.K.; Chao, S.T.; Weil, R.J.; Suh, J. et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 2111-2117. [CrossRef] [PubMed]
8. Sperduto, P.W.; Kased, N.; Roberge, D.; Xu, Z.; Shanley, R.; Luo, X.; Sneed, P.K.; Chao, S.T.; Weil, R.J.; Suh, J. et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 2012, 30, 419-425. [CrossRef] [PubMed]
9. Patchell, R.A.; Tibbs, P.A.; Walsh, J.W.; Dempsey, R.J.; Maruyama, Y.; Kryscio, R.J.; Markesbery, W.R.; Macdonald, J.S.; Young, B. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990, 322, 494-500. [CrossRef] [PubMed]
10. Vecht, C.J.; Haaxma-Reiche, H.; Noordijk, E.M.; Padberg, G.W.; Voormolen, J.H.; Hoekstra, F.H.; Tans, J.T.; Lambooij, N.; Metsaars, J.A.; Wattendorff, A.R. et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann. Neurol. 1993, 33, 583-590. [CrossRef] [PubMed]
11. Patchell, R.A.; Tibbs, P.A.; Regine, W.F.; Dempsey, R.J.; Mohiuddin, M.; Kryscio, R.J.; Markesbery, W.R.; Foon, K.A.; Young, B. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998, 280, 1485-1489. [CrossRef] [PubMed]
12. Brown, P.D.; Asher, A.L.; Ballman, K.V.; Farace, E.; Cerhan, J.H.; Anderson, S.K.; Carrero, X.W.; Barker, F.G.; Deming, R.L.; Burri, S. et al. NCCTG N0574 (alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. In Proceedings of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015.
13. Deeken, J.F.; Loscher, W. The blood-brain barrier and cancer: Transporters, treatment, and trojan horses. Clin. Cancer Res. 2007, 13, 1663-1674. [CrossRef] [PubMed]
14. De Vries, N.A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J.H.; van Tellingen O. P-glycoprotein and breast cancer resistance protein: Two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res. 2007, 13, 6440-6449. [CrossRef] [PubMed]
15. Yonemori, K.; Tsuta, K.; Ono, M.; Shimizu, C.; Hirakawa, A.; Hasegawa, T.; Hatanaka, Y.; Narita, Y.; Shibui, S.; Fujiwara, Y. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010, 116, 302-308. [CrossRef] [PubMed]
16. Witzel, I.; Oliveira-Ferrer, L.; Pantel, K.; Muller, V.; Wikman, H. Breast cancer brain metastases: Biology and new clinical perspectives. Breast Cancer Res. 2016, 18, 8. [CrossRef] [PubMed]
17. Berghoff, A.S.; Venur, V.A.; Preusser, M.; Ahluwalia, M.S. Immune checkpoint inhibitors in brain metastases: From biology to treatment. In Proceedings of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2016; pp. 116-122.
18. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673-1684. [CrossRef] [PubMed]
19. Leyland-Jones, B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 2009, 27, 5278-5286. [CrossRef] [PubMed]
20. Palmieri, D.; Bronder, J.L.; Herring, J.M.; Yoneda, T.; Weil, R.J.; Stark, A.M.; Kurek, R.; Vega-Valle, E.; Feigenbaum, L.; Halverson, D. et al. HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67, 4190-4198. [CrossRef] [PubMed]
21. Pestalozzi, B.C.; Brignoli, S. Trastuzumab in CSF. J. Clin. Oncol. 2000, 18, 2349-2351. [PubMed]
22. Stemmler, H.J.; Schmitt, M.; Willems, A.; Bernhard, H.; Harbeck, N.; Heinemann, V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18, 23-28. [CrossRef] [PubMed]
23. Dijkers, E.C.; Oude Munnink, T.H.; Kosterink, J.G.; Brouwers, A.H.; Jager, P.L.; de Jong, J.R.; van Dongen, G.A.; Schroder, C.P.; Lub-de Hooge, M.N.; de Vries, E.G. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87, 586-592. [CrossRef] [PubMed]
24. Tamura, K.; Kurihara, H.; Yonemori, K.; Tsuda, H.; Suzuki, J.; Kono, Y.; Honda, N.; Kodaira, M.; Yamamoto, H.; Yunokawa, M. et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J. Nucl. Med. 2013, 54, 1869-1875. [CrossRef] [PubMed]
25. Le Scodan, R.; Jouanneau, L.; Massard, C.; Gutierrez, M.; Kirova, Y.; Cherel, P.; Gachet, J.; Labib, A.; Mouret-Fourme, E. Brain metastases from breast cancer: Prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2011, 11, 395. [CrossRef] [PubMed]
26. Park, I.H.; Ro, J.; Lee, K.S.; Nam, B.H.; Kwon, Y.; Shin, K.H. Trastuzumab treatment beyond brain progression in her2-positive metastatic breast cancer. Ann. Oncol. 2009, 20, 56-62. [CrossRef] [PubMed]
27. Swain, S.M.; Baselga, J.; Kim, S.B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Heeson, S. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015, 372, 724-734. [CrossRef] [PubMed]
28. Swain, S.M.; Baselga, J.; Miles, D.; Im, Y.H.; Quah, C.; Lee, L.F.; Cortes, J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: Results from the randomized phase III study CLEOPATRA. Ann. Oncol. 2014, 25, 1116-1121. [CrossRef] [PubMed]
29. Nieder, C.; Andratschke, N.; Grosu, A.L.; Molls, M. Recursive partitioning analysis (rpa) class does not predict survival in patients with four or more brain metastases. Strahlenther. Onkol. 2003, 179, 16-20. [CrossRef] [PubMed]
30. Krop, I.E.; Lin, N.U.; Blackwell, K.; Guardino, E.; Huober, J.; Lu, M.; Miles, D.; Samant, M.; Welslau, M.; Dieras, V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in emilia. Ann. Oncol. 2015, 26, 113-119. [CrossRef] [PubMed]
31. Lin, N.U.; Carey, L.A.; Liu, M.C.; Younger, J.; Come, S.E.; Ewend, M.; Harris, G.J.; Bullitt, E.; van den Abbeele, A.D.; Henson, J.W. et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2008, 26, 1993-1999. [CrossRef] [PubMed]
32. Bachelot, T.; Romieu, G.; Campone, M.; Dieras, V.; Cropet, C.; Dalenc, F.; Jimenez, M.; Le Rhun, E.; Pierga, J.Y.; Goncalves, A. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (landscape): A single-group phase 2 study. Lancet Oncol. 2013, 14, 64-71. [CrossRef]
33. Cortes, J.; Dieras, V.; Ro, J.; Barriere, J.; Bachelot, T.; Hurvitz, S.; Le Rhun, E.; Espie, M.; Kim, S.B.; Schneeweiss, A. et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-breast 3): A randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015, 16, 1700-1710. [PubMed]
34. Freedman, R.A.; Bullitt, E.; Sun, L.; Gelman, R.; Harris, G.; Ligibel, J.A.; Krop, I.E.; Partridge, A.H.; Eisenberg, E.; Winer, E.P. et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin. Breast Cancer 2011, 11, 376-383. [CrossRef] [PubMed]
35. Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.Y.; Dieras, V.; Guardino, E. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367, 1783-1791. [CrossRef] [PubMed]
36. 2+metastatic breast cancer (MBC), including patients (PTS) with brain metastases. In Proceedings of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2016.
37. Mehta, M.P.; Paleologos, N.A.; Mikkelsen, T.; Robinson, P.D.; Ammirati, M.; Andrews, D.W.; Asher, A.L.; Burri, S.H.; Cobbs, C.S.; Gaspar, L.E. et al. The role of chemotherapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96, 71-83. [CrossRef] [PubMed]
38. Taskar, K.S.; Rudraraju, V.; Mittapalli, R.K.; Samala, R.; Thorsheim, H.R.; Lockman, J.; Gril, B.; Hua, E.; Palmieri, D.; Polli, J.W. et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 2012, 29, 770-781. [CrossRef] [PubMed]
39. Polli, J.W.; Humphreys, J.E.; Harmon, K.A.; Castellino, S.; O’mara, M.J.; Olson, K.L.; John-Williams, L.S.; Koch, K.M.; Serabjit-Singh, C.J. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 2008, 36, 695-701. [CrossRef] [PubMed]
40. Lin, N.U.; Dieras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H.J.; Roche, H.; Liu, M.C.; Greil, R.; Ciruelos, E. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 2009, 15, 1452-1459. [CrossRef] [PubMed]
41. Lim, E.; Lin, N.U. Updates on the management of breast cancer brain metastases. Oncology 2014, 28, 572-578. [PubMed]
42. Freedman, R.A.; Gelman, R.S.; Wefel, J.S.; Melisko, M.E.; Hess, K.R.; Connolly, R.M.; van Poznak, C.H.; Niravath, P.A.; Puhalla, S.L.; Ibrahim, N. et al. Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 2016. [CrossRef] [PubMed]
43. Lin, N.U.; Freedman, R.A.; Miller, K.; Jhaveri, K.L.; Eiznhamer, D.A.; Berger, M.S.; Hamilton, E.P. Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC). In Proceedings of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2016.
44. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357, 2666-2676. [CrossRef] [PubMed]
45. Miles, D.W.; Dieras, V.; Cortes, J.; Duenne, A.A.; Yi, J.; O’Shaughnessy, J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann. Oncol. 2013, 24, 2773-2780. [CrossRef] [PubMed]
46. Lin, N.U.; Gelman, R.S.; Younger, W.J.; Sohl, J.; Freedman, R.A.; Sorensen, A.G.; Bullitt, E.; Harris, G.J.; Morganstern, D.; Schneider, B.P. et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). In Proceedings of the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 31 May-4 June 2013.
47. Lu, Y.S.; Chen, T.W.; Lin, C.H.; Yeh, D.C.; Tseng, L.M.; Wu, P.F.; Rau, K.M.; Chen, B.B.; Chao, T.C.; Huang, S.M. et al. Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin. Cancer Res. 2015, 21, 1851-1858. [CrossRef] [PubMed]
48. Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006, 18, 77-82. [CrossRef] [PubMed]
49. Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13, 283-296. [CrossRef] [PubMed]
50. Lee, J.J.; Loh, K.; Yap, Y.S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol. Med. 2015, 12, 342-354. [PubMed]
51. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
52. Baselga, J.; Campone, M.; Piccart, M.; Burris, H.A III; Rugo, H.S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K.I.; Lebrun, F. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366, 520-529. [CrossRef] [PubMed]
53. Andre, F.; O’Regan, R.; Ozguroglu, M.; Toi, M.; Xu, B.; Jerusalem, G.; Masuda, N.; Wilks, S.; Arena, F.; Isaacs, C. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014, 15, 580-591. [CrossRef]
54. Franz, D.N.; Belousova, E.; Sparagana, S.; Bebin, E.M.; Frost, M.; Kuperman, R.; Witt, O.; Kohrman, M.H.; Flamini, J.R.; Wu, J.Y. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013, 381, 125-132. [CrossRef]
55. Cox, M.C.; Dan, T.D.; Swain, S.M. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin. Emerg. Drugs 2006, 11, 489-501. [CrossRef] [PubMed]
56. Walshe, J.M.; Denduluri, N.; Berman, A.W.; Rosing, D.R.; Swain, S.M. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin. Breast Cancer 2006, 6, 535-539. [CrossRef] [PubMed]
57. Choi, Y.J.; Anders, L. Signaling through cyclin D-dependent kinases. Oncogene 2014, 33, 1890-1903. [CrossRef] [PubMed]
58. Hamilton, E.; Infante, J.R. Targeting CDK4/6 in patients with cancer. Cancer Treat. Rev. 2016, 45, 129-138. [CrossRef] [PubMed]
59. Turner, N.C.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Huang Bartlett, C.; Zhang, K. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2015, 373, 209-219. [CrossRef] [PubMed]
60. Sahebjam, S.; Le Rhun, E.; Kulanthaivel, P.; Turner, P.K.; Klise, S.; Wang, H.T.; Tolaney, S.M. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. In Proceedings of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2016.
61. Stemmler, H.J.; Heinemann, V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: A treatment challenge. Oncology 2008, 13, 739-750. [CrossRef] [PubMed]
62. Kumthekar, P.; Tang, S.-C.; Brenner, A.J.; Kesari, S.; Piccioni, D.E.; Anders, C.K.; Carrillo, J.A.; Chalasani, P.; Kabos, P.; Puhalla, S. et al. ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer. In Proceedings of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2016.
63. Ramakrishna, N.; Temin, S.; Chandarlapaty, S.; Crews, J.R.; Davidson, N.E.; Esteva, F.J.; Giordano, S.H.; Gonzalez-Angulo, A.M.; Kirshner, J.J.; Krop, I. et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32, 2100-2108. [CrossRef] [PubMed]